|
| Exchange Received Time 17/09/2019 13:58:39 Exchange Disseminated Time 17/09/2019 13:58:47 Time Taken 00:00:08 | In accordance with Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby inform you that the Company has entered into the following Agreements:
1. Vide an agreement dated 16.09.2019, acquisition of the entire (100%) Equity Share Capital of OPAL Pharmaceuticals Pty Ltd (a company incorporated in Australia, hereinafter referred to as 'OPAL') (the 'Target Company') from its existing shareholders for a consideration aggregating up to (AU) $ 420,000. On completion of all the closing formalities, the Target Company will become a 100% Subsidiary of the Company.
2. Subsequently, vide an agreement dated 17.09.2019, disposal/sale of 25% Equity Share Capital of OPAL held by the Company to Baxyran Healthcare Private Limited (the 'Buyer') for a consideration of Rs. 51, 53,400/- Only . Therefore, post the aforesaid transfer, OPAL shall cease to be Company's WOS and the Company will become holder of 75% Equity Share Capital in the said subsidiary.
|
|
|